Dancing in Chaos: The Need for a Classification System for Chorea

Le résumé fourni par la source

Ethical Compliance Statement: This manuscript was carried out in accordance with the World Medical Association Declaration of Helsinki. IRB approval was waived, given the type of manuscript and that no identifiable personal information is included. Informed patient consent was not necessary for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the previous 12 months: AM has received grant funding from the Dystonia Medical Research Foundation (DMRF), Sunflower Parkinson's disease Foundation, and Parkinson's Foundation. He served on the advisory board of Adaptive Biosciences through the Parkinson's Study Group. He serves or has served as a consultant for Vima Therapeutics Inc. and AskBio Inc. He receives a stipend for serving as an Associate Editor for the MDCP journal. He received honorarium from MDS, AAN, ANA, PSG, IAPRD, NANS, Continuum, and the Texas Alzheimer's Research and Care Consortium (TARCC). AM has received grant support from the Huntington's Disease Society of America (HDSA) and UCLA's Chicano Studies Research Center. She has received honoraria from the American Academy of Neurology, served in the speakers bureau for Clinical Education Alliance, and has provided consultation for Neurocrine Biosciences. KZ has received an honorarium from the American Academy of Neurology. AJE has received grant support from the NIH and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies” with which he cofounded REGAIN Therapeutics to fund preclinical studies. He has no financial relationship with the company and has relinquished the right to any personal income from future treatments. AJE owns no stock in any pharmaceutical company with which he has an advisory relationship. CMT received honoraria for clinical trial steering committee work sponsored by Neurocrine and uniQure and speaker honorarium from the Virginia Neurological Society; scientific consulting funds from LifeEdit, LoQus23 and Klick Health; book co-editor royalties from Oxford University Press; research funding from the Parkinson's Foundation (PD GENEration), Sage Therapeutics and AskBio (clinical trial contracts with UNC-CH); and salary from the University of North Carolina at Chapel Hill. RHW receives research funding from the Department of Veterans Affairs and consultant fees from Teladoc, Inc. She has previously received consultant fees from Neurocrine Biosciences. EFS receives grant/research funding from Roche/Genentech, CHDI Foundation, Huntington's Disease Society of America, Huntington Study Group (Prilenia), MJFF, NIH/University of Iowa, Roche/Genentech, Sage Therapeutics, and UniQure. She received personal compensation for consulting to MedPage, Mescape, PTC Therapeutics, Latus Bio, Teva Pharmaceuticals, and Wave Life Sciences. She has or will receive compensation for her professional role from the following organizations: Huntington Study Group (Neurocrine, Principal Investigator, Chair of HSG Executive Membership Committee), UniQure (Steering Committee), and Skyhawk Therapeutics (DSMB). VS receives grant/research funding from MeiraGTx, LLC, and Ono Pharmaceuticals. She received personal compensation for consulting for Scion NeuroStim, Inc. All other authors have nothing to declare. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.